Jean‐Philippe Julien

This study identifies germline-encoded features as the primary driver of immunodominance in antibody responses to SARS-CoV-2, using structural modeling and mutational analysis.

This study uses gene-edited hematopoietic stem cells to create long-lived B lymphocyte protein factories that produce therapeutic antibodies against HIV-1, malaria, and influenza.

The paper determines the structure of the Pfs230:Pfs48/45 complex bound to transmission-blocking antibodies, revealing molecular interactions and epitopes that inform vaccine development.

This paper introduces TRACeR-II, a platform for developing MHC-II binders using a single loop, demonstrating its versatility and applicability to SARS-CoV-2 peptides.

This study reveals the structural basis of Plasmodium vivax inhibition by antibodies targeting the CSP repeats through molecular dynamics simulations and crystal structure analysis of inhibitory monoclonal antibodies.

The paper describes a multimerization platform that transforms antibodies into potent, broad-spectrum neutralizers against SARS-CoV-2.

The paper identifies SEMA6A and SEMA6B as receptors for C. sordellii lethal toxin and shows how mutations can switch receptor specificity between related toxins.